A Comparative Study Efficacy of Ondansetron versus Granisetron to Prevent Perioperative Nausea and Vomiting among Patients Under going Gynaecological Surgery under Spinal Anaesthesia in a Tertiary Care Hospital of Western India (original) (raw)
Related papers
Anaesthesia, 1993
The efficacy and safety of ondansetron in preventing postoperative nausea and vomiting.fol1owing major gynaecological surgery was evaluated in this multicentre, double-blind study. A total of 243 patients were randomised to receive three doses of oral ondansetron 8 mg or matching placebo at &hourly intervals, nith the first dose being given an hour before surgery. A standard general anaesthetic technique was employed throughout. Nausea, vomiting and safety assessments were performed continuously during the 24 h postrecovery period. Of the 237 patients evaluated for eficacy, signijicantly fewer ondansetron 8 mg treated patients (6511 17; 56%) experienced postoperative nausea andlor vomiting compared with placebo-treated patients (94/120; 78%) during the stud?. period (p < 0.001). In addition, ondansetron 8 mg reduced the severity of nausea (p < 0.001) and the total number of vomiting episodes experienced (p < 0.001). Overall. ondansetron 8 mg was well tolerated and effective in preventing postoperative nausea and vomiting in this surgical setting.
IP Innovative Publication Pvt. Ltd., 2019
Context: Postoperative Nausea and Vomiting (PONV) is associated with many adverse events, which prolong and increase the healthcare cost. Aims: To compare the efficacy of Palanosetron with respect to Granisetron and Ondansetron in prevention of PONV. To study the need of rescue antiemetic and incidence of side effects. Settings and Design: This Prospective, Randomized study was carried out with 150 adult female patients of ASA Grade I & II posted for elective gynecological surgery under GA. Materials and Methods: Patients were divided into three groups of 50 patients each. Group O received injection ondansetron 8 mg IV, Group G received Granisetron 2.5 mg IV & Group P received Palanosetron 0.075 mg iv before GA induction. Episodes of nausea, vomiting, need for rescue antiemetic and side effects were observed for 72 hours in postoperative period. Statistical Analysis Used: Graphpad Software with consideration of significant P value <0> Results: Incidence of nausea and vomiting was more with Ondansetron and minimal with Palanosetron with statistical significance of P< 0> Lowest incidence of nausea was found with Palanosetron during 3-24 hours postoperatively (P<0> Complete Control of PONV (No PONV, No rescue drug required) was maximum in P group in all hours of study [P<0> Conclusion: Palanosetron is safe, well tolerated and effective than Granisetron and Ondansetron in reducing the incidence of PONV with less need of rescue antiemetics. Key Messages: Palanosetron is proved better antiemetic than granisetron and ondansetron in prevention of PONV. Keywords: General Anaesthesia, Granisetron, Gynaecological surgery, Ondansetron, Palanosetron, Postoperative nausea and vomiting.
Journal of the Bangladesh Society of Anaesthesiologists, 2014
Background Post operative nausea and vomiting (PONV) is a common problem following general as well as regional anaesthesia. This causes great distress to the patient, may worsen surgical outcome and prolongs hospital stay. Prophylatic use of antiemetic in the preoperative or postoperative period reduces PONV. Objectives The study was designed to compare antiemetic effects of intravenous use of granisetron and ondansetron in the peroperative period for prevention of PONV following elective gynaecological surgery under general anaesthesia. Methods 60 (sixty) patients undergoing elective gynaecological surgery (total abdominal hysterectomy) under general anaesthesia of ASA grade I and II aged between 35-50 years were selected randomly and divided into two groups (group 'O' & group 'G') of thirty patients each. Patients of group 'O' received intravenous Inj, ondansetron 0.1 mg/kg body weight & group 'G' received intravenous Inj. granisetron 2 mg bolus over 30 sec just before peritoneal closure. Both the group received a standard general anaesthesia. Postoperative analgesia was provided with diclofenac suppository (50mg) and ketorolac tromethamine 30mg intra-muscularly. In the recovery room occurrence of post operative nausea and vomiting was assessed for 12 hours. All data were compiled and analyzed for statistical significance by Student's 't' tests (unpaired). P<0 .05 (CL 95%) was considered as significance. Results The incidence of post operative nausea and vomiting was reduced in both groups but no significant difference between the groups. No haemodynamic or psycho-mimetic adverse events were observed in the patients.
Canadian Journal of Anaesthesia, 1993
A single iv dose of ondansetron 8 mg prior to induction of anaesthesia reduces postoperative nausea and vomiting in gynaecological patients The effect of a single intravenous dose of ondansetron in preventing postoperative nausea and emesis (retching and vomiting) (PONV) was investigated in a randomized, double-blind, placebo-controlled, muhicentre, international study. Women of ASA class 1-111, requiring gynaecological laparotomy, vaginal hysterectomy, or major vaginal surgery were selected for study. Two hundred and thirty-j'we received placebo, 231 received I mg ondansetron, 228 received 8 mg ondansetron and 229 received 16 mg ondansetron, as an infusion over five minutes before the induction of anaesthesia. A standardized balanced anaesthetic technique was employed. This consisted of premedication with either diazepam or temazepam, thiopentone induction, maintenance with nitrous oxide in oxygen supplemented with enflurane or isoflurane, intraoperative analgesia with fentanyl, neuromuscular blockade with any choice of agent and reversal
Journal of Evolution of Medical and Dental Sciences
BACKGROUND The antiemetic action of 5-hydroxytryptamine receptor antagonists (5HT3 receptor blockers) has been well established. The present study compared the efficacy of the 5HT3 receptor blockers Ondansetron and Granisetron, in reducing the Post-Operative Nausea and Vomiting in day care gynaecological laparoscopic surgeries. Aims and Objectives-To compare the efficacy of intravenous Ondansetron versus Granisetron in the prevention of post-operative nausea and vomiting in patients undergoing day care gynaecological laparoscopic surgeries. MATERIALS AND METHODS 60 patients of ASA Grade 1 and II, between 18-55 years of age undergoing day care gynaecological surgeries were included in the present study. They were allocated into 2 groups of 30 each. The sample size was taken for convenience during the study. Group A received 4 mg (2 mL) of Ondansetron intravenously, Group B received 2 mg (2 mL) of Granisetron intravenously prior to induction of general anaesthesia. Each of these groups were assessed for the incidence of post-operative nausea, pain, emesis and adverse effects. RESULTS Incidence of nausea in the first 2 hrs. was the same in both the groups 16.6% (n= 5). The overall incidence of nausea in 0 to 24 hrs. in Group A and Group B was 23.3% (n= 7) and 20% (n= 6) respectively. The overall incidence of emesis in 0-24 hrs. after the surgery was found to be similar 6.6% (n= 2) in both the groups. No adverse effects were observed in both the groups. There was no statistically significant difference between Ondansetron and Granisetron with regards to their efficacy in minimising postoperative nausea and vomiting (p value > 0.05). CONCLUSION In conclusion, intravenous administration of 4 mg Ondansetron or 2 mg Granisetron prior to induction of general anaesthesia is equally effective in preventing the post-operative nausea and vomiting in day care gynaecological laparoscopic surgeries.
Aim: Our aim of this randomized & prospective clinical study was to investigate and compare the efficacy of palonosetron HCl and granisetron HCl to prevent postoperative nausea and vomiting after gynaecological surgery. Method: Fifty female patients of ASA grade I and II in between 18-60 years of age posted for elective gynaecological surgery were randomly divided into two groups containing 25 patients each. Before induction of anaesthesia group P received bolus dose of palonosetron 75 mcg and group G received bolus dose of granisetron 2.5 mg intravenously slowly over a period of 30 seconds. Result: In the postoperative period (0-3 hrs), the incidence of complete response (no postoperative nausea & vomiting, no rescue medication) was 88% with palonosetron and 76% with granisetron (p value-0.46) .During 3-24 hrs postoperatively the incidence was 92% with palonosetron and 80% with granisetron (p value-0.417). During 24-48 hrs postoperatively the incidence was 92 % with palonosetron and 60 % with granisetron (p value-0.018). During 48-72 hrs incidence was statistically insignificant (p value-0.1284). Insignificant incidence of side effects between the groups was found. Conclusion: Palonosetron is more potent and long acting than granisetron for the prevention of post operative nausea & vomiting after gynaecological surgery.
Combination of ondansetron and dexamethasone in the prophylaxis of postoperative nausea and vomiting
British Journal of Anaesthesia, 1996
We studied 100 ASA I-II females undergoing general anaesthesia for major gynaecological surgery, in a prospective, double-blind, placebocontrolled, randomized study. Patients received one of four regimens for the prevention of postoperative nausea and vomiting (PONV): ondansetron 4 mg (n : 25), dexamethasone 8 mg (n : 25), ondansetron with dexamethasone (4 mg and 8 mg, respectively, n : 25) or placebo (saline, n : 25) There were no differences in background factors or factors related to operation and anaesthesia, morphine consumption, pain or side effects between groups. The incidence of nausea and emetic episodes in the ondansetron with dexamethasone group was lower than in the placebo (P : 0.01), ondansetron (P : 0.05) and dexamethasone (P : 0.057) groups. There were no differences between ondansetron and dexamethasone, and both were more effective than placebo (P : 0.05 and P : 0.01, respectively). Dexamethasone appeared to be preferable in preventing nausea than emetic episodes. Fewer patients in the ondansetron with dexamethasone group needed antimetic rescue (P : 0.01 vs placebo and P : 0.05 vs ondansetron). We conclude that prophylactic administration of combined ondansetron and dexamethasone is effective in preventing PONV. (Br.
Journal of Evolution of medical and Dental Sciences, 2015
OBJECTIVE: To compare the efficacy and safety of Granisetron versus Ondansetron in prevention of post-operative nausea and vomiting in patients undergoing elective Laparoscopic Cholecystectomy under general anaesthesia. MATERIALS AND METHODS: After the approval from IEC, the study was started and conducted over a period of two years i.e., from 2010-2012. Data was collected from 100 ASA I and II patients scheduled for laparoscopic cholecystectomy aged between 20-60 years at Government General Hospital, Kakinada. Both the study groups were selected from these patients. Written informed consent was taken from all patients. Preanesthetic medication was given with Ranitidine 150mg and Lorazepam 1mg, the night before and morning of surgery. Patients were randomly allocated into 2 groups. Group A Received Inj. Ondansetron 8mg diluted in 5ml of normal saline. Group B Received Inj. Granisetron 1mg diluted in 5ml of normal saline. INJ. Glycopyrolate 0.01mg/kg & INJ. Fentanyl (1-2μ/Kg) given i...
Single-dose i.v. granisetron in the prevention of postoperative nausea and vomiting
British Journal of Anaesthesia, 1996
In this randomized, double-blind, parallel group, placebo-controlled, dose-ranging study, we have compared three doses (0.1 mg, 1.0 mg and 3.0 mg) of the 5-HT 3 receptor antagonist, granisetron (Kytril), as prophylactic therapy for the prevention of postoperative nausea and vomiting. The aims were to determine the optimal dose of granisetron and to evaluate its safety profile. We studied 527 adult patients, undergoing elective open abdominal surgery or vaginal hysterectomy during general anaesthesia. Antiemetic prophylaxis with a single dose of granisetron 1.0 mg or 3.0 mg resulted in a significant reduction (P : 0.001 compared with placebo) in the numbers of patients experiencing postoperative vomiting, or nausea, or who achieved total control during the postoperative periods 0-6 h and 0-24 h. The two higher doses of granisetron (1.0 mg and 3.0 mg) provided effective prophylaxis against vomiting, with 78 % and 77 % of patients, respectively, being free from vomiting in the first 6 h after surgery, and 63 % and 62 % in the first 24 h. This compares with 50 % and 34 % at 0-6 h and 0-24 h, respectively, in the placebo group. Granisetron was well tolerated and the optimum dose was 1.0 mg. (Br.